Knight Therapeutics Inc. announces voting results from the Annual Meeting
11 Maio 2022 - 10:28PM
Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation")
a leading pan-American (ex-US) specialty pharmaceutical company,
announced today the voting results from the Annual Meeting of the
Shareholders held virtually in Montreal, Quebec ("Meeting").
Election of Directors
Each director nominee listed in the Management
Information Circular dated April 11, 2022 ("Circular") was elected
as Director of the Corporation at the Meeting. Shareholders present
in person or represented by proxy at the Meeting voted as
follows:
DIRECTOR NOMINEE |
OUTCOME |
VOTES FOR |
% FOR |
VOTES WITHELD |
% WITHELD |
Jonathan Ross Goodman |
Elected |
60,902,832 |
95.75% |
|
2,701,678 |
|
4.25% |
|
James C. Gale |
Elected |
63,265,174 |
99.47% |
|
339,336 |
|
0.53% |
|
Samira Sakhia |
Elected |
63,472,472 |
99.79% |
|
132,038 |
|
0.21% |
|
Robert N. Lande |
Elected |
60,537,287 |
95.18% |
|
3,067,223 |
|
4.82% |
|
Michael J. Tremblay |
Elected |
57,178,604 |
89.90% |
|
6,425,906 |
|
10.10% |
|
Nicolás Sujoy |
Elected |
60,678,074 |
95.40% |
|
2,926,436 |
|
4.60% |
|
Janice Murray |
Elected |
63,124,888 |
99.25% |
|
479,622 |
|
0.75% |
|
Appointment of external Auditors
Ernst & Young LLP were appointed as external
auditors of the Corporation for the next year by a majority of the
votes cast by the shareholders present or represented by proxy, and
the directors were authorized to determine their remuneration.
Shareholders present in person or represented by proxy at the
Meeting voted as follows:
OUTCOME |
VOTES FOR |
% FOR |
VOTES WITHHELD |
% WITHHELD |
Appointed |
63,633,816 |
99.78% |
141,491 |
0.22% |
Approval of unallocated rights under the
Corporation’s employee share purchase plan (“ESPP”)
The resolution to approve unallocated rights
under the Corporation’s employee share purchase plan for the
ensuing three years, as described in the Circular, was approved by
a majority of the votes cast by the shareholders present or
represented by proxy. Shareholders present in person or represented
by proxy at the Meeting voted as follows:
OUTCOME |
VOTES FOR |
% FOR |
VOTES AGAINST |
% AGAINST |
Approved |
50,507,892 |
79.41% |
13,096,618 |
20.59% |
The results of the final votes regarding all
matters subject to a vote during the Meeting will also be made
available on SEDAR (www.sedar.com).
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in
Montreal, Canada, is a specialty pharmaceutical company focused on
acquiring or in-licensing and commercializing pharmaceutical
products for Canada and Latin America. Knight owns Biotoscana
Investments S.A., a pan-Latin American specialty pharmaceutical
company. Knight’s Latin American subsidiaries operate under United
Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics
Inc.'s shares trade on TSX under the symbol GUD. For more
information about Knight Therapeutics Inc., please visit the
company's web site at www.gud-knight.com or www.sedar.com.
Forward-Looking Statement
This document contains forward-looking
statements for Knight Therapeutics Inc. and its subsidiaries. These
forward-looking statements, by their nature, necessarily involve
risks and uncertainties that could cause actual results to differ
materially from those contemplated by the forward-looking
statements. Knight Therapeutics Inc. considers the assumptions on
which these forward-looking statements are based to be reasonable
at the time they were prepared but cautions the reader that these
assumptions regarding future events, many of which are beyond the
control of Knight Therapeutics Inc. and its subsidiaries, may
ultimately prove to be incorrect. Factors and risks, which could
cause actual results to differ materially from current expectations
are discussed in Knight Therapeutics Inc.'s Annual Report and in
Knight Therapeutics Inc.'s Annual Information Form for the year
ended December 31, 2021 as filed on www.sedar.com. Knight
Therapeutics Inc. disclaims any intention or obligation to update
or revise any forward-looking statements whether as a result of new
information or future events, except as required by law.
Investor Contact: |
|
|
Knight Therapeutics Inc. |
|
|
Samira Sakhia |
|
Arvind Utchanah |
President & Chief
Executive Officer |
|
Chief Financial Officer |
T: 514.484.4483 |
|
T. +598.2626.2344 |
F: 514.481.4116 |
|
|
Email: info@knighttx.com |
|
Email: info@knighttx.com |
Website: www.gud-knight.com |
|
Website: www.gud-knight.com |
Knight Therapeutics (TSX:GUD)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Knight Therapeutics (TSX:GUD)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024